Literature DB >> 24726362

ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.

Jason T Forys1, Catherine E Kuzmicki1, Anthony J Saporita1, Crystal L Winkeler1, Leonard B Maggi1, Jason D Weber2.   

Abstract

The ARF and p53 tumor suppressors are thought to act in a linear pathway to prevent cellular transformation in response to various oncogenic signals. Here, we show that loss of p53 leads to an increase in ARF protein levels, which function to limit the proliferation and tumorigenicity of p53-deficient cells by inhibiting an IFN-β-STAT1-ISG15 signaling axis. Human triple-negative breast cancer (TNBC) tumor samples with coinactivation of p53 and ARF exhibit high expression of both STAT1 and ISG15, and TNBC cell lines are sensitive to STAT1 depletion. We propose that loss of p53 function and subsequent ARF induction creates a selective pressure to inactivate ARF and propose that tumors harboring coinactivation of ARF and p53 would benefit from therapies targeted against STAT1 and ISG15 activation.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24726362      PMCID: PMC4157460          DOI: 10.1016/j.celrep.2014.03.026

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  45 in total

Review 1.  Complex roles of Stat1 in regulating gene expression.

Authors:  C V Ramana; M Chatterjee-Kishore; H Nguyen; G R Stark
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

2.  p53-independent functions of the p19(ARF) tumor suppressor.

Authors:  J D Weber; J R Jeffers; J E Rehg; D H Randle; G Lozano; M F Roussel; C J Sherr; G P Zambetti
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

3.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

4.  p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs.

Authors:  Katerina I Leonova; Leonid Brodsky; Brittany Lipchick; Mahadeb Pal; Liliya Novototskaya; Alex A Chenchik; Ganes C Sen; Elena A Komarova; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

5.  Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.

Authors:  M Sanchez-Cespedes; A L Reed; M Buta; L Wu; W H Westra; J G Herman; S C Yang; J Jen; D Sidransky
Journal:  Oncogene       Date:  1999-10-21       Impact factor: 9.867

6.  ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus.

Authors:  Anna Osiak; Olaf Utermöhlen; Sandra Niendorf; Ivan Horak; Klaus-Peter Knobeloch
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

Review 7.  The INK4a/ARF network in tumour suppression.

Authors:  C J Sherr
Journal:  Nat Rev Mol Cell Biol       Date:  2001-10       Impact factor: 94.444

8.  ISGylation governs the oncogenic function of Ki-Ras in breast cancer.

Authors:  J Burks; R E Reed; S D Desai
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

9.  The genomic landscape of breast cancer as a therapeutic roadmap.

Authors:  Matthew J Ellis; Charles M Perou
Journal:  Cancer Discov       Date:  2013-01       Impact factor: 39.397

10.  The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation.

Authors:  M J Kuchenreuther; J D Weber
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

View more
  29 in total

1.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

2.  Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.

Authors:  Nitin Mahajan; Hua-Jun Wu; Richard L Bennett; Catalina Troche; Jonathan D Licht; Jason D Weber; Leonard B Maggi; Michael H Tomasson
Journal:  FASEB J       Date:  2016-10-24       Impact factor: 5.191

3.  Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation.

Authors:  Jun-Bao Fan; Sayuri Miyauchi-Ishida; Kei-ichiro Arimoto; Dan Liu; Ming Yan; Chang-Wei Liu; Balázs Győrffy; Dong-Er Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-29       Impact factor: 11.205

4.  Deleting key autophagy elongation proteins induces acquirement of tumor-associated phenotypes via ISG15.

Authors:  EunBin Kong; Hag Dong Kim; Joon Kim
Journal:  Cell Death Differ       Date:  2020-03-03       Impact factor: 15.828

5.  PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage.

Authors:  HyeonJoo Cheon; Elise G Holvey-Bates; Daniel J McGrail; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 12.779

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

Review 7.  Nucleolus-derived mediators in oncogenic stress response and activation of p53-dependent pathways.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2016-05-03       Impact factor: 4.304

8.  IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer.

Authors:  Wei Tang; Tiffany A Wallace; Ming Yi; Cristina Magi-Galluzzi; Tiffany H Dorsey; Olusegun O Onabajo; Adeola Obajemu; Symone V Jordan; Christopher A Loffredo; Robert M Stephens; Robert H Silverman; George R Stark; Eric A Klein; Ludmila Prokunina-Olsson; Stefan Ambs
Journal:  Clin Cancer Res       Date:  2018-07-16       Impact factor: 12.531

9.  NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression.

Authors:  Delin Chen; Omid Tavana; Bo Chu; Luke Erber; Yue Chen; Richard Baer; Wei Gu
Journal:  Mol Cell       Date:  2017-10-05       Impact factor: 17.970

Review 10.  Regulation and action of interferon-stimulated gene 15 in breast cancer cells.

Authors:  Angeles C Tecalco-Cruz; Josué O Ramírez-Jarquín; Eduardo Cruz-Ramos
Journal:  Hum Cell       Date:  2020-08-19       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.